Preclinical Research in Down Syndrome: Insights for Pathophysiology and Treatments

Mara Dierssen is a Doctor in Medicine and Surgery from the University of Cantabria, (1989). She leads the Cellular and Systems Neurobiology laboratory at the Genomic Regulation Center (CRG) and is associate researcher of the Hospital del Mar Research Institute, where she promoted the creation of a translational research program to study new therapeutic approaches in intellectual disability. Her main current scientific interests are focused on the study of the neurobiological mechanisms underlying memory and learning and their alteration in complex diseases (polygenic and multifactorial) and in the development and application of this knowledge to the field of clinical practice.Among her scientific contributions in the field of neurobiology and neuropharmacology is the identification of the alterations of neuroplasticity in various intellectual deficiencies and psychiatric pathology, and the determination of their molecular mechanisms. She is internationally recognized in the study of Down syndrome, whose findings, especially the involvement of the DYRK1A gene in the neuronal pathology of this syndrome, have had a direct impact on the identification of new pharmacological targets. Dr. Dierssen has demonstrated for the first time significant beneficial effects of a pharmacological treatment that improves neuroplasticity in the field of intellectual disability, a finding that has revolutionized the therapeutic approaches in cognitive disorders. Her scientific interest in innovating tools and strategies, incorporating brain-computer interface technologies to improve communication in patients with cerebral palsy, or cognitive stimulation videogames are also in the forefront of Neuroscience. He has published more than 160 research papers in indexed scientific journals. At present, the H index (Hirsch Factor) of Dr. Dierssen is 46.Dr. Dierssen is one of the few Spanish members of the Europaea Academy of Sciences, and has held different positions of responsibility, being president of the Spanish Society of Neurosciences, the International Behavioral and Neural Genetics Society and the Trisomy 21 Research Society.She has obtained the Ramón Trías Fargas Prizes, National Prize of Thought and Scientific Culture of the Generalitat of Catalonia, Jaime Blanco, Sisley-Lejeune Award, Hillie-Mahoney Award, Trébol Down Spain Award, Optimists Committed Award, Trifermed Social Impact of Healthcare Award, BigVang Medalamong others. She has been named Distinguished Student of the University of Cantabria, and is an honorary member of the College of Physicians. She is elected member of the European Allianz for the Brain (EDAB), founding member of the Spanish Association for the Advancement of Science, member of the Scientific Council of the Pla de Ciència of Barcelona, among other positions.She has held teaching positions at the Ramón Llull University, the Autonomous University of Barcelona and the University of Cantabria, and has directed more than 20 doctoral theses and trained a large number of researchers, most of whom run their own groups in prestigious centers.

"It is important to recognize that trisomy 21 does not receive enough attention from the scientific community. This is a unique book that brings to the medical community the vast work still needed to understand trisomy 21 and to improve outcomes of individuals with Down syndrome. The Trisomy 21 Research Society has done an excellent job supporting this publication and Mara Dierssen has achieved her goals well in editing this extremely important contribution." --Doody

• 1. Genetic and epigenetic pathways in Down syndrome: Insights to the brain and immune system from humans and mouse modelsY. Eugene Yu, Zhuo Xing, Catherine Do, Annie Pao, Eun Joon Lee, Sharon Krinsky-McHale, Wayne Silverman, Nicole Schupf and Benjamin Tycko2. Influence of allelic differences in Down syndromeRandall J. Roper, Laura Hawley and Charles R. Goodlett3. Modeling Down syndrome in cells: From stem cells to organoidsGillian Gough, Niamh L. O'Brien, Ivan Alic, Pollyanna A. Goh, Yeap Yee Jie, Jurgen Groet, Dean Nizetic and Aoife Murray4. Modeling Down syndrome in animals from the early stage to the 4.0 models and nextMaria del Mar Muñiz Moreno, Véronique Brault, Marie-Christine Birling, Guillaume Pavlovic and Yann Herault5. Mapping behavioral landscapes in Down syndrome animal models María Martínez de Lagrán6. Using mouse models to understand Alzheimer’s disease mechanisms in the context of trisomy of chromosome 21Claudia Cannavo, Justin Tosh, Elizabeth M.C. Fisher and Frances K. Wiseman7. Focusing on cellular biomarkers: The endo-lysosomal pathway in Down syndromeAlexandra Botté and Marie-Claude Potier8. Translational validity and implications of pharmacotherapies in preclinical models of Down syndromeNoemí Rueda, Jesús Flórez, Mara Dierssen and Carmen Martínez-Cué9. Plasticity as a therapeutic target for improving cognition and behavior in Down syndromeCarmen Martínez-Cué and Mara Dierssen